Suprefort
What is it?
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
Identity / background source ↗
Research context
A named tissue-derived preparation with a recovered institute report. The linked evidence concerns this preparation and its study setting; clinical effectiveness remains uncertain.
- Working classification
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
- Study methods
- —Small comparative institute report; allocation, blinding and outcome interpretation require caution
- Independent replication
- —Independent replication not established in this collection
- Source access
- —Report reproduction linked; source language and review scope shown per record
- Safety evidence
- —Short-term reports do not establish long-term safety or equivalence to current products
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Explore the expanded peptide research collection and unresolved source trails ↗
View this preparation in the Khavinson evidence map ↗
Linked sources
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Explore the research map and unresolved leads ↗
Suprefort: clinical report on a tissue-derived preparation
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
The 2005–2006 report describes digestive-enzyme trends and glucose outcomes. The two-hour glucose comparison is marked significant against controls; fasting changes are marked against baseline.
- Population / setting
- 59 patients: pancreatitis 12 treated/8 controls; type-2 diabetes 22 treated/17 controls.
- What was checked
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Limitations & review scope
- Random allocation is asserted for the pancreatitis comparison without a method. Changing glucose-lowering co-treatment complicates attribution. This is not evidence for stopping diabetes medication.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Source checked 2026-10-02. This is a source-linked record, not a completed evidence review.